95 related articles for article (PubMed ID: 36034824)
1. The efficacy and safety of apatinib for refractory malignancies: a review and meta-analysis.
Sun D; Hou H; Zhang C; Zhang X
Onco Targets Ther; 2018; 11():6539-6554. PubMed ID: 30323627
[TBL] [Abstract][Full Text] [Related]
2. Anti-angiogenesis agents plus chemoradiotherapy for locally advanced nasopharyngeal cancer: a systematic review and meta-analysis.
Sun X; Zhu Y; Lou Y; Lu X; Wang B; Yu D; Guo Y; Xin Y
Eur Arch Otorhinolaryngol; 2024 Apr; ():. PubMed ID: 38625559
[TBL] [Abstract][Full Text] [Related]
3. Treatment-related toxicities of apatinib in solid tumors: a meta-analysis.
Peng L; Ye X; Hong Y; Zhang J; Dong Y; Zhao Q
Oncotarget; 2018 Aug; 9(63):32262-32270. PubMed ID: 30181815
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of selpercatinib in treating RET-altered MTC: A single-arm meta-analysis.
Huang D; Zhang J; Zheng X; Gao M
Heliyon; 2024 Jun; 10(11):e31681. PubMed ID: 38841496
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of apatinib versus sorafenib/placebo in first-line treatment for intermediate and advanced primary liver cancer: A systematic review and meta-analysis.
Peng D; Cai Y; Chen G; Hou M; Luo X; Dongzhi Z; Xie H; Liu Y
Front Pharmacol; 2023; 14():1101063. PubMed ID: 37153777
[No Abstract] [Full Text] [Related]
6. Meta-Analysis of Efficacy and Safety of Karelizumab Combined with Apatinib in the Treatment of Advanced Gastric Cancer.
Liu H; Li Y; Yao Y; Chen K; Gan J
Dis Markers; 2022; 2022():6971717. PubMed ID: 36193493
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Apatinib for the Treatment of Advanced or Recurrent Cervical Cancer: A Single-Arm Meta-Analysis Among Chinese Patients.
Huang D; He Q; Zhai L; Shen J; Jing F; Chen H; Zhu X; Zhou J
Front Pharmacol; 2022; 13():843905. PubMed ID: 36034824
[No Abstract] [Full Text] [Related]
8. Efficacy and safety of apatinib monotherapy for patients with advanced breast cancer: a systematic review and meta-analysis.
Huang X; Hu X; Yi T
Front Oncol; 2022; 12():940171. PubMed ID: 35978823
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis.
Lin H; Weng X; Wu X; Wu L
Transl Cancer Res; 2022 Jun; 11(6):1770-1780. PubMed ID: 35836539
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Efficiency and Safety of Apatinib in Advanced Bone and Soft Tissue Sarcomas: A Systematic Review and Meta-Analysis.
Long Z; Huang M; Liu K; Li M; Li J; Zhang H; Wang Z; Lu Y
Front Oncol; 2021; 11():662318. PubMed ID: 33816318
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of apatinib as second or later-line therapy in extensive-stage small cell lung cancer: a prospective, exploratory, single-arm, multi-center clinical trial.
Liu Q; Xu JY; Xu YH; Chen M; Deng LC; Wu JP; Zhou T; Zhang LQ; Tan J; Pu XX; Shang YL; Hua J; Li YQ; Cai W; Gu YL; Peng XC; Chan PC; Jabbour SK; Nam HS; Hua D
Transl Lung Cancer Res; 2022 May; 11(5):832-844. PubMed ID: 35693282
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and prognostic factors of apatinib treatment in patients with recurrent or advanced cervical carcinoma: A retrospective study.
Yang H; Chen M; Mei Z; Xie C; Zhou Y; Qiu H
Cancer Med; 2021 Jul; 10(13):4282-4290. PubMed ID: 33987959
[TBL] [Abstract][Full Text] [Related]
13. Normalization of the tumor microvasculature based on targeting and modulation of the tumor microenvironment.
Li Z; Ning F; Wang C; Yu H; Ma Q; Sun Y
Nanoscale; 2021 Oct; 13(41):17254-17271. PubMed ID: 34651623
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]